We are live on ! Find out more
ITOS

iTeos Therapeutics
ITOS

Delisted

ITOS was delisted on the 28th of August, 2025.

Back to rankings

1 hedge funds and large institutions have $2.35K invested in iTeos Therapeutics in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 135 closing their positions.

New
Increased
Maintained
Reduced
Closed

98.8% less ownership

Funds ownership: 98.8% → 0% (-99%)

99% less funds holding

Funds holding: 136 → 1 (-135)

100% less funds holding in top 10

Funds holding in top 10: 4 → 0 (-4)

100% less capital invested

Capital invested by funds: $377M → $2.35K (-$377M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 135

Holders
1
Holders Change
-135
Holders Change %
-99.26%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
135
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
IA
IFP Advisors
Florida
+$20

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$107M
2
BlackRock
BlackRock
New York
-$45.6M
3
TCM
Tang Capital Management
California
-$38.2M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$16.6M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$8.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
PCM
76
Prelude Capital Management
New York
– -$392K -39,349 Closed
VAM
77
Vazirani Asset Management
New York
– -$349K -35,000 Closed
XT
78
XTX Topco
Cayman Islands
– -$347K -34,777 Closed
Deutsche Bank
79
Deutsche Bank
Germany
– -$335K -33,556 Closed
BCM
80
Bluefin Capital Management
New York
– -$304K -30,530 Closed
A
81
AlphaQuest
New York
– -$289K -29,019 Closed
NRD
82
Nebula Research & Development
New York
– -$288K -28,909 Closed
YIH
83
Y-Intercept (HK)
Hong Kong
– -$283K -28,375 Closed
ACM
84
ADAR1 Capital Management
Texas
– -$269K -26,937 Closed
PCP
85
Proficio Capital Partners
Massachusetts
– -$248K -24,865 Closed
SIM
86
Sandia Investment Management
Massachusetts
– -$248K -24,865 Closed
Jane Street
87
Jane Street
New York
– -$229K -22,999 Closed
CM
88
Caption Management
Oklahoma
– -$221K -22,157 Closed
IIM
89
INTECH Investment Management
Florida
– -$207K -20,806 Closed
AA
90
ALPS Advisors
Colorado
– -$206K -20,653 Closed
GCM
91
Graham Capital Management
Connecticut
– -$206K -20,637 Closed
Wells Fargo
92
Wells Fargo
California
– -$201K -20,192 Closed
Two Sigma Advisers
93
Two Sigma Advisers
New York
– -$179K -18,000 Closed
MIM
94
MetLife Investment Management
New Jersey
– -$170K -17,001 Closed
Mirae Asset Global ETFs Holdings
95
Mirae Asset Global ETFs Holdings
Hong Kong
– -$163K -16,351 Closed
Tudor Investment Corp
96
Tudor Investment Corp
Connecticut
– -$154K -15,415 Closed
B
97
Bailard
California
– -$152K -15,200 Closed
T. Rowe Price Associates
98
T. Rowe Price Associates
Maryland
– -$150K -14,969 Closed
AC
99
AXQ Capital
New Jersey
– -$138K -13,860 Closed
Carson Wealth (CWM LLC)
100
Carson Wealth (CWM LLC)
Nebraska
– -$120K -12,013 Closed
2 3
4
5 6

ITOS Hedge Fund Activity: Q3 2025 in Review

1 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q3 2025, worth a combined $2.35K — down 100% from $377M a quarter earlier.

Sellers outnumbered buyers: 135 funds closed out of ITOS and 0 opened new positions — a net loss of 135 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was IFP Advisors, adding an estimated $20. The largest seller was EcoR1 Capital, exiting entirely with an estimated $107M sold.

  • 1 institutional investor held iTeos Therapeutics (ITOS) as of Q3 2025, down from 136 in Q2 2025.
  • Funds reported $2.35K of iTeos Therapeutics stock for Q3 2025, down 100% quarter-over-quarter.
  • 0 funds opened new iTeos Therapeutics positions in Q3 2025 and 135 closed out, a net change of -135 holders.
  • The largest iTeos Therapeutics buyer in Q3 2025 was IFP Advisors, an estimated $20 added.
  • The largest iTeos Therapeutics seller in Q3 2025 was EcoR1 Capital, an estimated $107M sold.

Based on aggregated 13F filings for Q3 2025.